Clinical Trial Update: A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 trial of PF-07901800 (TTI-621) in patients with hematologic malignancies and selected solid tumors was terminated, with results posted on 2024-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumor

Drugs mentioned

• PF-07901800 (TTI-621) (TTI-621)

Snippet

Sponsor: Pfizer | Conditions: Hematologic Malignancies, Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2024-05-10